Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21128
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRösler, Thomas W-
dc.contributor.authorTayaranian Marvian, Amir-
dc.contributor.authorBrendel, Matthias-
dc.contributor.authorNykänen, Niko-Petteri-
dc.contributor.authorHöllerhage, Matthias-
dc.contributor.authorSchwarz, Sigrid C-
dc.contributor.authorHopfner, Franziska-
dc.contributor.authorKoeglsperger, Thomas-
dc.contributor.authorRespondek, Gesine-
dc.contributor.authorSchweyer, Kerstin-
dc.contributor.authorLevin, Johannes-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorBarthel, Henryk-
dc.contributor.authorSabri, Osama-
dc.contributor.authorMüller, Ulrich-
dc.contributor.authorMeissner, Wassilios G-
dc.contributor.authorKovacs, Gabor G-
dc.contributor.authorHöglinger, Günter U-
dc.date2019-06-22-
dc.date.accessioned2019-07-08T05:20:50Z-
dc.date.available2019-07-08T05:20:50Z-
dc.date.issued2019-09-
dc.identifier.citationProgress in neurobiology 2019; 180: 101644en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21128-
dc.description.abstractTau is a microtubule-associated protein with versatile functions in the dynamic assembly of the neuronal cytoskeleton. Four-repeat (4R-) tauopathies are a group of neurodegenerative diseases defined by cytoplasmic inclusions predominantly composed of tau protein isoforms with four microtubule-binding domains. Progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease or glial globular tauopathy belong to the group of 4R-tauopathies. The present review provides an introduction in the current concept of 4R-tauopathies, including an overview of the neuropathological and clinical spectrum of these diseases. It describes the genetic and environmental etiological factors, as well as the contemporary knowledge about the pathophysiological mechanisms, including post-translational modifications, aggregation and fragmentation of tau, as well as the role of protein degradation mechanisms. Furthermore, current theories about disease propagation are discussed, involving different extracellular tau species and their cellular release and uptake mechanisms. Finally, molecular diagnostic tools for 4R-tauopathies, including tau-PET and fluid biomarkers, and investigational therapeutic strategies are presented. In summary, we report on 4R-tauopathies as overarching disease concept based on a shared pathophysiological concept, and highlight the challenges and opportunities on the way towards a causal therapy.en
dc.language.isoeng-
dc.subject4R-tauopathyen
dc.subjectAlzheimer’s diseaseen
dc.subjectArgyrophilic grain diseaseen
dc.subjectCorticobasal degenerationen
dc.subjectGlial globular tauopathyen
dc.subjectMicrotubule-Associated protein tauen
dc.subjectProgressive supranuclear palsyen
dc.titleFour-repeat tauopathies.en
dc.typeJournal Articleen
dc.identifier.journaltitleProgress in neurobiologyen
dc.identifier.affiliationDept. of Neurology, Hannover Medical School, 30625 Hannover, Germanyen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDept. of Neurology, University of Munich, 81377 Munich, Germanyen
dc.identifier.affiliationGerman Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germanyen
dc.identifier.affiliationDept. of Neurology, Technical University of Munich, School of Medicine, 81675 Munich, Germanyen
dc.identifier.affiliationService de Neurologie, CHU Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, Franceen
dc.identifier.affiliationCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France; Dept. of Medicine, University of Otago, Christchurch, New Zealanden
dc.identifier.affiliationNew Zealand Brain Research Institute, Christchurch, New Zealanden
dc.identifier.affiliationInstitute of Neurology, Medical University of Vienna, 1090 Vienna, Austriaen
dc.identifier.affiliationDept. of Laboratory Medicine and Pathobiology, University of Toronto, Laboratory Medicine Program, University Health Network, Toronto, Canadaen
dc.identifier.affiliationTanz Centre for Research in Neurodegenerative Disease, Krembil Brain Institute, Toronto, Canadaen
dc.identifier.affiliationMunich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germanyen
dc.identifier.affiliationDept. of Neurology, Technical University of Munich, School of Medicine, 81675 Munich, Germany.en
dc.identifier.affiliationDept. of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, 3084, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDept. of Nuclear Medicine, University of Munich, 81377 Munich, Germany.en
dc.identifier.affiliationDept. of Psychiatry, University of Munich, 80336 Munich, Germanyen
dc.identifier.affiliationDept. of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germanyen
dc.identifier.affiliationInstitute for Human Genetics, University of Giessen, 35392 Giessen, Germanyen
dc.identifier.doi10.1016/j.pneurobio.2019.101644en
dc.type.contentTexten
dc.identifier.pubmedid31238088-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherVillemagne, Victor L
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

58
checked on Nov 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.